Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
277 AUD | -1.02% | +0.93% | -3.35% |
03:14am | Australian shares retreat as miners, banks drag; CBA down on lower profit | RE |
May. 07 | Australia's CSL tests 'dynamic pricing' of donor blood amid cost surge | RE |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.44 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.35% | 88.91B | A- | ||
+2.76% | 41.25B | A- | ||
-14.30% | 31.99B | B- | ||
+50.51% | 24.73B | A | ||
-14.97% | 15.54B | C | ||
-39.93% | 12.07B | B | ||
-9.08% | 12.05B | D+ | ||
-14.91% | 12.02B | B- | ||
+6.22% | 8.84B | B+ | ||
-5.15% | 8.3B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CSL Stock
- Ratings CSL Limited